CD38-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


«12345678910111213...1415»
  • ||||||||||  Review, Journal:  Novel approaches to the treatment of multiple myeloma. (Pubmed Central) -  May 9, 2023   
    In the relapsed setting, the emergence of B-cell maturation antigen-directed therapy, including antibody-drug conjugates, chimeric antigen receptor T-cell therapy, and more recently, bispecific antibodies, has produced deep and durable responses in heavily pretreated patients. This review article describes novel approaches to the treatment of MM in both the newly diagnosed and the relapsed/refractory setting.
  • ||||||||||  Review, Journal, IO biomarker:  Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End? (Pubmed Central) -  Apr 28, 2023   
    Most recently, the bispecific anti-BCMA and T-cell-engaging antibody teclistamab has become available, again for patients with relapsed/refractory disease...However, belantamab remains a drug with some promise, and many other ADCs targeting either BCMA or other plasma cell surface markers are in development and showing potential. This contribution will provide an overview of some of the current data supporting the possibility that ADCs will remain a part of our chemotherapeutic armamentarium against myeloma moving forward, and also highlight areas for future development.
  • ||||||||||  STI-6129 / Sorrento
    Enrollment change, Trial initiation date, Trial withdrawal:  An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis (clinicaltrials.gov) -  Apr 28, 2023   
    P1,  N=0, Withdrawn, 
    This contribution will provide an overview of some of the current data supporting the possibility that ADCs will remain a part of our chemotherapeutic armamentarium against myeloma moving forward, and also highlight areas for future development. N=36 --> 0 | Initiation date: Mar 2023 --> Sep 2023 | Not yet recruiting --> Withdrawn
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6241;    
    P1b/2, P2b
    In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall survival was in the range of 1 year, akin to historical results seen with ADCs. The 8-week median time between administration of selinexor and NCAs suggests that selinexor, with various partner agents, did not negatively impact overall survival with subsequent NCA therapy.
  • ||||||||||  Darzalex (daratumumab) / J&J, talquetamab (JNJ-64407564) / J&J
    Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. (Live Stream | Hall D2) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_1371;    
    P1b
    Steroid-sparing tal + dara showed deep and durable responses with promising mPFS in heavily pretreated pts with RRMM, including pts refractory to anti-CD38/BCMA and T-cell redirecting therapy, suggesting combined immunomodulatory actions can yield robust responses in pts with refractory disease. The safety profile was clinically manageable; no new signals were identified with longer follow-up.
  • ||||||||||  MEDI2228 / AstraZeneca, Darzalex (daratumumab) / J&J, Blenrep (belantamab mafodotin) / GSK
    ANTIBODY DRUG CONJUGATES (ADCS) () -  Apr 26, 2023 - Abstract #EMN2023EMN_215;    
    P3
    Belantamab Mafodotin (belamaf) is the first approved anti-BCMA ADC for the treatment of relapsed/refractory multiple myeloma (RRMM)...Three-phase III studies evaluate the safety and efficacy of belamaf in combination with pomalidomide (NCT04162210; DREAMM-3), daratumumab plus bortezomib (NCT04246047; DREAMM-7), or pomalidomide plus bortezomib (NCT04484623: DREAMM-8)...MEDI2228 has shown potent antitumor activity in preclinical models, including cell lines resistant to lenalidomide. Phase 1 data in heavily pretreated patients were encouraging.
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK
    DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN (Poster Area) -  Apr 4, 2023 - Abstract #EMN2023EMN_189;    
    The ongoing DREAMM-5 trial interrogates the addition of the gamma-secretase inhibitor Nirogacestat to minimize sBCMA levels in patients treated with Belantamab Mafodotin. Our novel finding of TFsBCMA suggests that it may be of additional value to also track TFsBCMA levels in these patients, and that such a strategy, lowering sBCMA levels, may not only increase treatment efficiency but may also hold potential to reduce ocular side effects under Belantamab Mafodotin therapy.
  • ||||||||||  Treatment of triple-class refractory disease: beyond immunotherapy (Grote Zaal) -  Apr 4, 2023 - Abstract #EMN2023EMN_63;    
    In addition, venetoclax has demonstrated significant activity in t(11;14) MM patients and represents another therapeutic option. The most appropriate sequencing of existing therapies and the most potent treatment combination still remains unanswered.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Daratumumab rescue therapy in a patient with anti-MDA5 associated ARDS (Poster View) -  Apr 2, 2023 - Abstract #EULAR2023EULAR_1996;    
    Conclusion Rescue immunosuppressive therapy of MDA5-antibody associated ARDS with daratumumab in addition to tofacitinib, ciclosporin and prednisolone was associated with remarkable clinical improvement in this case. More clinical data and long-term follow-up are needed to investigate safety and efficacy of this treatment regimen in MDA5-antibody-associated disease.
  • ||||||||||  Review, Journal:  Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma. (Pubmed Central) -  Mar 17, 2023   
    A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.
  • ||||||||||  Darzalex (daratumumab) / J&J
    An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells (Section 36; Poster Board #2) -  Mar 14, 2023 - Abstract #AACR2023AACR_5701;    
    It is estimated that a very minute amount, probably less than 0.01%, of intraperitoneally injected lenalidomide gets into the transplanted MM tumor in the mouse model. TE-1146 may be a more effective and less toxic drug than Daratumumab/Lenalidomide combination in treating patients with hard-to-treat MM.
  • ||||||||||  MT-5111 / Molecular Templates, MT-6402 / Molecular Templates, MT-0169 / Molecular Templates
    Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile (Section 13; Poster Board #29) -  Mar 14, 2023 - Abstract #AACR2023AACR_4885;    
    ETBs can also deliver additional payloads to drive unique biology like the alteration of tumor immunophenotype. Here we describe three active clinical stage programs with encouraging safety and efficacy data that represent a transformation of the immunotoxin landscape into a more viable therapeutic approach to target validated as well as typically intractable clinical cancer targets.
  • ||||||||||  Review, Journal:  Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma. (Pubmed Central) -  Mar 4, 2023   
    The most important are: CD38 (daratumumab and isatuximab), SLAM7 (elotuzumab), and BCMA (belantamab mafodotin) for the treatment of MM currently used in clinical practice. Although the disease is still incurable, the future perspective is to find the best therapeutic combination among all available drugs.
  • ||||||||||  STI-6129 / Sorrento
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date:  STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis (clinicaltrials.gov) -  Feb 27, 2023   
    P1,  N=0, Withdrawn, 
    Nurses play a crucial role in identifying and managing AEs and educating patients about cilta-cel. N=62 --> 0 | Trial completion date: Apr 2027 --> Feb 2023 | Initiation date: Feb 2023 --> Aug 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2027 --> Feb 2023
  • ||||||||||  TNB-738 / TeneoFour, Inc, Ancora Biotech
    Trial completion date, Trial primary completion date:  A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers (clinicaltrials.gov) -  Feb 16, 2023   
    P1,  N=80, Recruiting, 
    N=62 --> 0 | Trial completion date: Apr 2027 --> Feb 2023 | Initiation date: Feb 2023 --> Aug 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2027 --> Feb 2023 Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Jan 2024
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Towards the optimal PET tracer for multiple myeloma imaging (Room 211 (Indiana Convention Center)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_10494;    
    Additionally, modulation of the pharmacokinetics of the radioimmunoconjugate platform results in the modification of imaging times and radiation doses which could hold important clinical implications.In vivo evaluation of 89Zr-DFO-Isatuximab in a disseminated model of MM. MIP images at 144h in control and block cohort.
  • ||||||||||  Immunophenotypic profile of acute leukemia in yemen (In-Person) -  Jan 13, 2023 - Abstract #HEMATOLOGY2023HEMATOLOGY_19;    
    Flow cytometry, even with a 3-colour strategy, is able to give useful diagnostic information about cell lineage of acute leukaemias. This has proven beneficial for patient management.
  • ||||||||||  Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi, Blenrep (belantamab mafodotin) / GSK
    Review, Journal:  Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. (Pubmed Central) -  Jan 9, 2023   
    Despite the impressive clinical efficacy of these new strategies in the treatment of newly diagnosed or multi-refractory MM patients, several mechanisms of resistance have already been described, including antigen downregulation, the impairment of antibody-dependent cell cytotoxicity and phagocytosis, T- and natural killer cell senescence, and exhaustion. In this review, we summarize the current knowledge on the mechanisms of action and resistance of anti-CD38 and anti-BCMA agents and their clinical efficacy and safety.